Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor that was investigated for the treatment for acute coronary syndrome. In 2013 Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.
This page contains content from the copyrighted Wikipedia article "Otamixaban"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
